CliffBio
small molecule

RINVOQ LQ

UPADACITINIB

Loss of exclusivityOctober 2036latest FDA-listed patent expiry
CompanyAbbVie Inc. →View the full company profile on CliffBio

Drug detail

Brand nameRINVOQ LQ
Active ingredientUPADACITINIB
Strength1MG/ML
Dosage formSOLUTION
RouteORAL
ModalitySmall molecule
FDA approvalApril 2024
Marketing statusRX

Listed patents

PatentExpiresType
11186584October 2036substance
11773105October 2036substance
12365689October 2036use U-3945
9951080October 2036substance
10981923October 2036substance
11680069October 2036substance
12110298October 2036substance
11718627October 2036substance
11661425October 2036substance
RE47221August 2033substance
8962629January 2031substance

Regulatory exclusivity

CodeExpires
ODE-481April 2031
NPApril 2027

More from AbbVie Inc.

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

RINVOQ LQ patent cliff — loss of exclusivity October 2036 | CliffBio